Celcuity Inc.
CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedaā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$56.26
Price+3.29%
$1.79
1Y
Price
Market Cap
$2.387b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$121.340k
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$148.710m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$3.45
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$44.375m
$183.592m
Assets$139.217m
Liabilities$99.415m
DebtDebt to Assets
54.2%
-0.7x
Debt to EBITDAFree Cash Flow
-$84.740m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company